Jefferies upgrades Chemed as Medicare cap risk eases and buybacks support stock

Jefferies upgraded Chemed Corp to Buy from Hold, primarily due to a significant reduction in regulatory risk for its VITAS Healthcare hospice unit. This improvement stems from successful mitigation of Medicare reimbursement caps and better-than-expected 2026 Medicare rates, which are now projected to lower potential liabilities to under $5 million from a prior estimate of up to $25 million. The firm now forecasts Chemed's 2026 EBITDA at the upper end of Street estimates, further bolstered by anticipated aggressive share repurchases utilizing most of its $480 million authorization in the second half of 2025, which is expected to support near-term valuation.

Analysis

Jefferies has upgraded Chemed Corp. (CHE) to Buy from Hold, citing a significant reduction in regulatory risk for its VITAS Healthcare hospice division. A primary concern regarding Medicare reimbursement caps, which was previously estimated to create a potential liability of $18 million to $25 million, is now projected to result in a financial impact below $5 million. This revised outlook is attributed to successful mitigation strategies, including a focus on short-stay patients and new operations, as well as more favorable 2026 Medicare rates. Consequently, Jefferies anticipates Chemed's 2026 EBITDA will reach the upper end of consensus estimates, with the VITAS unit forecast to achieve 6% to 8% growth and margins between 17.5% and 18.5%. Further supporting the positive thesis is the company's aggressive capital return strategy, with plans to deploy most of its $480 million share repurchase authorization in the second half of 2025, which should provide near-term valuation support. While the Roto-Rooter plumbing business remains a source of uncertainty, encouraging July trends and a potentially beneficial shift in contractor demand following a future Federal Reserve rate cut offer potential upside.

Key Decisions for Investors

• Investors should re-evaluate Chemed's risk profile, as the upgrade signals the primary regulatory overhang on the hospice business has been materially reduced, potentially justifying a higher valuation multiple.
• The planned deployment of a $480 million share buyback authorization in H2 2025 acts as a significant near-term catalyst and a source of valuation support, signaling strong management confidence.
• Monitor performance data from the Roto-Rooter segment and macroeconomic indicators like Fed rate decisions, as these are the main remaining uncertainties that could either restrain or accelerate the company's consolidated results.